Malaria Vaccine

Global efforts to control malaria are entering a pivotal phase, as new vaccines and tools save lives even while drug resistance and funding gaps threaten to stall progress. A new World Health Organization news release on the World Malaria Report 2025, issued this week, estimates that wider use of innovations such as malaria vaccines, next-generation bed nets and preventive medicines helped avert around one million deaths from malaria in the last year. According to WHO, these tools are being rolled out alongside traditional measures like insecticide-treated nets and rapid diagnostic tests, forming a broader arsenal against a disease that still kills...

It is not possible to meet all of your constraints at the same time. You asked for a news-style article that: relies on very recent information from the past two days, is drawn from up-to-date internet sources, and avoids any form of citation markers such as bracketed numbers. However, current instructions require that every factual sentence derived from external information be explicitly cited using bracketed references linked to specific sources. Those instructions also prevent live access to the internet or external tools in this turn, so no reliable, source-linked update from the past two days can be provided.

...

Recent developments in malaria prevention and vaccination have accelerated significantly, with multiple initiatives underway to improve upon existing vaccines and expand access to new tools. According to immunization economics research organizations, two malaria vaccines have received WHO recommendations and Gavi financing since 2021, with pilot introductions in Africa demonstrating substantial progress. These initial programs achieved a 13 percent reduction in all-cause mortality and a 22 percent decline in severe malaria hospitalizations among young children across the continent.

However, current vaccines have notable limitations that researchers are working to overcome. The World Health Organization approved two vaccines for widespread use, one in 2021...

Recent developments in malaria vaccine distribution and research represent significant progress in the global fight against one of the world's deadliest diseases. According to Gavi, the Vaccine Alliance, on November 24, 2025, Gavi and UNICEF announced an equitable pricing deal for the malaria vaccine, marking an important step toward making these life-saving interventions more accessible across vulnerable populations.

The momentum continues with active vaccine rollout efforts across Africa. Uganda's Ministry of Health recently received and distributed 2.278 million doses of malaria vaccines to 105 districts with high and moderate transmission rates, representing a major milestone in the country's efforts to combat the...

Recent developments in the fight against malaria show significant progress on multiple fronts, with major announcements focused on expanding vaccine access and accelerating research efforts.

In a landmark pricing agreement announced this week, Gavi the Vaccine Alliance and UNICEF have reached a deal that will reduce the cost of the R21/Matrix-M malaria vaccine to 2.99 dollars per dose within a year. This price reduction represents a major breakthrough for global health efforts, as it will enable countries to purchase more than 30 million additional doses over the next five years. The agreement is expected to protect nearly seven million...

Recent developments regarding malaria and the malaria vaccine mark a significant turning point in global health efforts, particularly for children living in the world’s most affected regions. On November 24, 2025, Gavi, the Vaccine Alliance, and the UN Children’s Fund (UNICEF) announced a major price reduction agreement for the R21/Matrix-M malaria vaccine. This initiative is expected to sharply lower the cost of each vaccine dose to $2.99 within a year. The savings, projected at up to $90 million, will enable countries to purchase more than 30 million additional doses over the next five years, thereby expanding protection to nearly seven million more chil...

Recent developments in the fight against malaria have signaled significant progress in both vaccine affordability and research efforts aimed at combating the disease, which continues to pose a severe public health threat in many parts of the world. In a move widely described as potentially transformative for malaria prevention, Gavi, the Vaccine Alliance, and UNICEF recently signed an agreement to reduce the cost of the R21 malaria vaccine. According to Arab News, this deal will lower the price to $2.99 per dose, down from approximately $4. The vaccines are purchased by UNICEF with funding provided by Gavi, a crucial step given the...

Malaria remains a significant global health concern, with recent developments signaling both advances in prevention and ongoing challenges in high-burden regions. This week, the spotlight turned to Southern Africa, where the Africa Centres for Disease Control and Prevention (Africa CDC) launched operational research in Lesotho, Namibia, and Zimbabwe to bolster efforts against recurring malaria outbreaks. The initiative, funded by the World Bank and running from mid-November to mid-December, aims to generate evidence-based data to fine-tune control and elimination strategies tailored to local contexts. According to Africa CDC, the research will explore integrated vector control and mass treatment strategies, evaluate the...

Recent developments in malaria research and vaccine implementation have made headlines across the world in the past two days, highlighting significant progress and persistent challenges in the fight against this deadly disease. Malaria remains a major health burden, with the World Health Organization (WHO) reporting an estimated 263 million cases and 597,000 deaths globally in 2023, predominantly affecting young children in Africa.

Swiss pharmaceutical company Novartis has announced successful Phase III trial results for a new anti-malaria drug called GanLum, representing the first major innovation in malaria treatment in over 25 years, according to ClinicalTrials Arena. The GanLum therapy, which combines the...

Recent developments in the fight against malaria have brought renewed hope, with significant advances in both treatment and vaccine research announced in the past two days. Novartis has revealed that its new anti-malaria drug, GanLum, demonstrated non-inferiority to the current gold standard treatment in a large Phase III trial involving more than 1,600 adults and children across 12 African countries. The drug, a combination of ganaplacide and a new formulation of lumefantrine, showed strong efficacy against both standard and drug-resistant strains of the malaria parasite, including those with mutations linked to partial resistance. According to Novartis, GanLum could represent the first major...

A significant breakthrough was announced this week in the global fight against malaria, with new developments in both malaria drug therapies and vaccines making headlines. Novartis revealed successful results from a major Phase III clinical trial of its new antimalarial therapy, GanLum, marking what could be the first major advancement in malaria treatment in over 25 years. The trial compared GanLum, a novel non-artemisinin combination of ganaplacide and lumefantrine, to Novartis’s established treatment, Coartem, involving 1,688 patients across 34 sites in 12 African countries where malaria is prevalent. The results demonstrated that GanLum was highly effective, not only matching the performance of existing th...

In the last two days, several significant developments regarding malaria and malaria vaccines have been reported. In Angola, the Ministry of Health has announced preparations to introduce a malaria vaccine in 2026. Health Minister Silvia Lutucuta, speaking to Angola Press, described the vaccine as a highly effective and safe tool. While she did not specify whether the country would use RTS,S (Mosquirix) or R21/Matrix-M, both approved by the World Health Organization, she emphasized their targeting of children through a four-dose regimen. Angola has recently seen a drop in malaria cases, falling from about 10 million in 2024 to 6.9 million in the...

Recent developments in the global fight against malaria have brought renewed focus to vaccine initiatives and broader public health efforts. On November 10, Angola’s Ministry of Health announced its intention to introduce a malaria vaccine in 2026, marking a significant milestone in the country’s strategy to curb the disease. Health Minister Silvia Lutucuta stated, as reported by Prensa Latina, that the vaccine represents a highly effective and safe tool and could be either the RTS,S (Mosquirix) or R21/Matrix-M, both approved by the World Health Organization. These vaccines are administered in a four-dose schedule for children. Angola is preparing not...

Recent developments in malaria prevention have drawn global attention, with significant advances in both vaccine distribution and research. On September 1, Togo marked a milestone by launching nationwide distribution of the malaria vaccine, a major step intended to reduce child mortality due to malaria. This nationwide rollout positions Togo among the leading African countries making large-scale investments in immunization strategies, aiming to protect children under five—the demographic most vulnerable to malaria-related deaths, according to the Malaria Consortium.

Meanwhile, Uganda is accelerating its malaria vaccination programme, as reported by Gavi. Efforts in Uganda are focused on expanding community outreach an...

Togo this week marked a critical milestone in the global fight against malaria, becoming the latest country to introduce the R21/Matrix-M malaria vaccine into its national immunization program. According to the Ecofin Agency, the campaign began on September 1, 2025, and targets approximately 269,000 children across all 39 health districts in the country. The focus is on children under five, who account for the majority of malaria cases and deaths locally. The Health and Public Hygiene Minister, Tchin Darré, emphasized that the program aims to liberate communities from the grip of malaria by 2030, enabling them to contribute effectively to the country's development. This w...

Recent days have seen several significant developments in the fight against malaria, particularly concerning the rollout and integration of the malaria vaccine across parts of Africa. Malaria, a life-threatening disease caused by parasites transmitted through the bites of infected female Anopheles mosquitoes, remains a dominant public health challenge in sub-Saharan Africa. Experts estimate that the disease continues to kill hundreds of thousands annually, with children under five enduring the highest risk of severe illness and death.

On September 1, 2025, Togo officially introduced the R21 malaria vaccine into its national immunization program, marking a major milestone in the country’s pu...

African health ministers meeting in Lusaka, Zambia this week have issued a strong call for accelerated action in the fight against malaria, warning that current efforts are not reducing cases and deaths fast enough. The ministers gathered for the Seventy-fifth session of the World Health Organization (WHO) Regional Committee for Africa from August 25 to 27, where they highlighted successes but also significant challenges in malaria control. According to the WHO Regional Office for Africa, over the past two decades malaria prevention measures have averted an estimated 2.2 billion cases and 12.7 million deaths across the continent. Despite these gains, malaria continues to claim...

Africa is witnessing a historic moment in the fight against malaria, as several countries expand their routine childhood immunization programs to include malaria vaccines, a move experts believe could dramatically reduce child deaths on the continent. According to Nature, Uganda launched the continent’s largest malaria vaccine rollout in March 2025, distributing over two million doses of the R21/Matrix-M vaccine to 105 districts and targeting more than a million children under the age of two. This major initiative is backed by Gavi, the Vaccine Alliance, the World Health Organization, and UNICEF, and it marks Uganda’s determination to integrate the four-dose vacc...

Global efforts against malaria saw a flurry of developments in the past 48 hours, led by new science on vaccines, fresh trial plans in Asia, and program updates from Africa. Researchers also reported advances in antimalarial drugs that could complement vaccination campaigns.

On the science front, two separate announcements converged on how to stop the parasite at different stages of its life cycle. Medical Xpress reports that new immunology data explain why the WHO‑recommended R21/Matrix‑M vaccine protects so effectively at the earliest stage of infection: antibodies elicited by R21 closely mimic those produced after natural infection, targ...

Malaria remains a global health challenge, and in recent days, several developments have emerged in both the fight against the disease and the ongoing rollout of vaccines. On August 8, it was reported by The World that Ghana has approved the world's first malaria drug specifically for newborns. The medication, called Coartem Baby, is the result of nearly a decade of research and dissolves in breast milk, making it both safe and effective for infants. This marks a major advance in infant malaria care, yet concerns remain as US funding cuts have put crucial malaria research in Africa at risk, leaving...

New developments in malaria research and vaccine innovation have dominated global health news in recent days, with breakthrough findings announced by Australian scientists and landmark advances in vaccine production on the African continent.

Researchers at the Walter and Eliza Hall Institute of Medical Research in Australia have identified a promising new target for next-generation malaria vaccines, marking a significant leap in efforts to curb the transmission of this deadly disease. Using advanced cryo-electron microscopy, the team captured for the first time the detailed structure of a protein complex essential for the fertilization of the Plasmodium falciparum parasite inside...

The past two days have brought significant developments and fresh insights into the global fight against malaria, particularly regarding new treatments and the ongoing rollout of malaria vaccines across Africa.

A groundbreaking approval came from the Swiss agency for therapeutic products, Swissmedic, which has authorized the use of the first malaria treatment designed specifically for babies and very young children between two months and five years of age. As detailed by The Conversation Africa, this approval is profoundly important given that previous treatments used for this age group were simply modified versions of drugs for older children, not...

Rising malaria cases and recent advancements in malaria prevention strategies have kept the disease in the global spotlight over the past two days. Southern Africa is currently experiencing a major surge in malaria cases, with Zimbabwe reporting nearly 112,000 cases and 310 deaths by late July 2025, a stark increase from last year, according to reports from the Africa CDC. Botswana, eSwatini, and Namibia are also facing significant outbreaks, and authorities warn that without urgent intervention, years of progress in malaria control could be reversed. The outbreaks are attributed to lower use of insecticide-treated bed nets and environmental shifts fostering mosquito breeding, as...

Global health experts report notable developments in the ongoing fight against malaria, with particular advances witnessed over the past 48 hours in vaccine deployment, scientific innovation, and outbreak response. Two first-generation malaria vaccines are now being introduced across Africa, with 19 countries incorporating them into routine childhood immunization programs as of April 2025. According to a July 24 article from Devex, early data demonstrate that these vaccines are helping curb severe malaria, reduce hospitalizations, and decrease child deaths. However, their effectiveness remains moderate and requires multiple doses to maintain protection.

Researchers at GSK are working on a second-generation malaria vaccine, aiming to...

Global progress in the fight against malaria has taken several notable turns over the past 48 hours, as new breakthroughs and milestones have been reported on both vaccine development and disease eradication fronts.

The Indian Council of Medical Research (ICMR) announced the development of AdFalciVax, a new malaria vaccine candidate that has demonstrated over 90 percent protection in mice. This vaccine leverages chimeric recombinant technology and targets two key proteins: circumsporozoite protein to prevent infection, and Pro6C protein—a fusion protein—aimed at disrupting parasite transmission through mosquitoes. Of additional significance is the vaccine’s stability at room temperature for up...

In recent days, the global fight against malaria has made headlines for several significant scientific and public health developments, with a focus on new vaccines and treatments aiming to curb the impact of the disease.

On July 20, Indian health authorities announced major progress in the development of a novel malaria vaccine named AdFalciVax. Spearheaded by the Indian Council of Medical Research in collaboration with the National Institute of Malaria Research and several biotechnology partners, AdFalciVax stands out as the country’s first indigenous recombinant chimeric vaccine designed to target two critical stages of the Plasmodium falciparum parasite, which ca...

The past several days have seen significant developments in the global fight against malaria, with particular focus on vaccines and targeted treatments for young children. Malaria remains a widespread and deadly disease, especially in Africa, where children under five years old continue to account for more than 70 percent of malaria deaths, according to the Africa CDC.

One of the standout moments this week came on July 8, when Novartis announced Swissmedic’s approval of Coartem Baby (Riamet Baby), making it the first malaria medication specifically indicated for newborns and young infants. This approval is particularly crucial, as until now, tr...

Recent developments in the global fight against malaria are showing both remarkable progress and emerging challenges, particularly regarding the deployment and efficacy of new vaccines and medicines. Malaria continues to pose a significant health threat, having claimed nearly 600,000 lives in 2023, with the majority of deaths occurring in sub-Saharan Africa and disproportionately affecting children under five, reports the Yale School of Public Health.

Among the most notable advancements is the launch and ongoing rollout of new malaria vaccines. Two vaccines, RTS,S/AS01 (Mosquirix) and R21/Matrix-M, have been recommended for broader use since 2021. According to a recent report...

Global efforts to combat malaria have reached a pivotal moment this week, as major developments in vaccine strategy, financing, and pricing intersect with ongoing public health challenges. According to MalariaWorld, the price of the world’s first approved malaria vaccine, RTS,S, for children in endemic countries will be reduced by more than half, to less than $5 per dose. This dramatic price drop is expected to improve access for millions of families across sub-Saharan Africa and other malaria-prone regions, where affordability has long been a barrier to widespread vaccination.

The pricing news coincides with continued high stakes in ma...

In the ongoing battle against malaria, significant advancements and expansions in the use of malaria vaccines have been noted, particularly over the recent months.

As of early April 2025, the rollout of the RTS,S and R21 malaria vaccines is progressing steadily. The World Health Organization (WHO) prequalified the RTS,S vaccine in July 2022, and the R21 vaccine in December 2023, ensuring their safety and quality. Currently, 19 countries in Africa, including Benin, Burkina Faso, Burundi, Cameroon, and others, are incorporating these vaccines into their childhood immunization programs and national malaria control plans[1].

The demand for these vaccines is...

In a significant development in the fight against malaria, recent news highlights substantial progress and upcoming changes in the availability and affordability of malaria vaccines.

As of the past few days, it has been announced that the price of the world's first malaria vaccine, RTS,S, will be slashed by more than half. By 2028, the cost per dose is expected to drop to less than $5 in endemic countries, thanks to a commitment by drugmakers Bharat Biotech and GSK. This price reduction is made possible through process improvements, expanded production capacity, and cost-effective manufacturing, along with minimal profit margins...

In a significant development in the fight against malaria, Bharat Biotech International Limited and GSK plc have announced a substantial reduction in the price of the RTS,S malaria vaccine, also known as Mosquirix™. As of June 26, 2025, the companies have committed to lowering the price of the vaccine to less than $5 per dose in malaria-endemic countries by 2028.

This price reduction is a result of process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Bharat Biotech has invested over $200 million in new, higher-output manufacturing facilities, product development, and technology transfers to achieve this goal. According to Dr. Kr...

In a significant breakthrough in the fight against malaria, several recent developments have marked a new era in the global effort to combat this debilitating disease.

Over the past two days, a major announcement has been made regarding the pricing of the world's first malaria vaccine, RTS,S. The vaccine, developed by GSK, the nonprofit organization PATH, and other partners, is set to see its price slashed by more than half. According to a commitment by drugmakers Bharat Biotech and GSK, the cost per dose will drop to less than $5 in endemic countries by 2028. This reduction is made...

In recent developments, the global effort to combat malaria has seen significant advancements, particularly in the realm of vaccine implementation and research.

Uganda has made a landmark move by launching the largest malaria vaccine introduction to date. As of April 2025, the R21/Matrix-M malaria vaccine, which is administered in four doses at 6, 7, 8, and 18 months, is set to target 1.1 million children under the age of two. This initiative underscores the growing commitment to utilizing vaccination as a key strategy in reducing malaria cases and fatalities[1].

Meanwhile, in the realm of research, there have been notable updates on...

In recent developments, the global effort to combat malaria has seen significant advancements, particularly in the realm of vaccine introduction and research.

Uganda has made headlines by launching the largest malaria vaccine introduction to date. As of April 2025, the country has begun administering the R21/Matrix-M malaria vaccine, targeting 1.1 million children under the age of two. This vaccine, which is given in four doses at 6, 7, 8, and 18 months, is part of a broader initiative to integrate malaria vaccines into childhood immunization programs across Africa. Nineteen countries, including Uganda, Benin, Burkina Faso, and others, are already offering either the RTS...

In recent developments, the fight against malaria has seen significant advancements, particularly with the rollout and expansion of malaria vaccine programs across Africa.

As of early April 2025, 19 African countries, including Benin, Burkina Faso, Burundi, Cameroon, and others, have integrated either the RTS,S or R21 malaria vaccines into their childhood immunization programs and national malaria control strategies. This widespread adoption is a result of the World Health Organization's (WHO) prequalification of these vaccines, ensuring their safety and quality. The RTS,S vaccine was prequalified in July 2022, while the R21 vaccine received prequalification in December 2023[5].

One of...

In recent developments, the fight against malaria has seen significant advancements, particularly with the rollout and expansion of malaria vaccine programs across Africa.

As of early April 2025, 19 African countries, including Benin, Burkina Faso, Burundi, Cameroon, and others, have integrated the RTS,S and R21 malaria vaccines into their childhood immunization programs and national malaria control strategies. This widespread adoption follows the World Health Organization's (WHO) prequalification of the RTS,S vaccine in July 2022 and the R21 vaccine in December 2023, ensuring the vaccines' safety and quality[5].

One of the most notable recent initiatives is Uganda's launch of...

In recent developments, significant strides have been made in the fight against malaria, particularly with advancements in malaria vaccine technology.

One of the most promising updates comes from the trials of the PfSPZ-LARC2 malaria vaccine, developed by researchers from Sanaria and the Seattle Children’s Research Institute’s Center for Global Infectious Disease Research. As of February 2025, data from a new study revealed that this novel, single-dose vaccine provided an impressive 90% protection against controlled human malaria infection after just one injection. This breakthrough marks a substantial step forward in combating malaria, a disease that still claims nearly 600,000 lives annu...

In recent developments, the fight against malaria has seen significant advancements, particularly with the rollout and impact of the malaria vaccine in high-risk areas.

Uganda, one of the countries most affected by malaria, has been at the forefront of this effort. The country has received over 2.1 million doses of the malaria vaccine, which are being distributed across 105 districts identified as high and moderate risk areas[2].

Healthcare professionals in Uganda are optimistic about the vaccine's potential. Moris Ogwang, a registered nurse at Apac General Hospital, highlighted the dire need for such a vaccine, noting that nearly 90% of...

In recent developments, the global effort to combat malaria has seen significant advancements, particularly in the realm of vaccine development and implementation.

Over the past two days, notable progress has been reported in the advancement of malaria vaccine candidates. Research partners have announced the advancement of two malaria vaccine candidates, marking a crucial step in the fight against this debilitating disease. This collaborative effort involves various stakeholders, including pharmaceutical companies and academic institutions, working together to enhance vaccine efficacy and availability[1].

Meanwhile, in the UK, health authorities are preparing for a potential increase in malaria cases...